Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression
复制标题
DOI：
10.1038/sj.leu.2404220
复制
发表时间：
2006-06-01
期刊：
影响因子：
11.4
通讯作者：
Jaeger, U.
中科院分区：
文献类型：
--
作者：
Bilban, M.;Heintel, D.;Jaeger, U.
脂蛋白脂酶（LPL）是与免疫球蛋白V-H基因（IgV（H））突变状态相关的B细胞慢性淋巴细胞白血病（B-CLL）的预后标志物。我们使用Affyssin U133 A基因芯片在两组选择为高（“LPL+”，n = 10）或低（“LPL-”，n = 10）LPL mRNA表达的B-CLL中确定基因表达谱。在扩展的患者队列（n 42）中通过实时PCR验证选定的基因。总共111个基因区分LPL+与LPL-B-CLL。其中，与首次治疗时间相关的前三位基因是Septin 10、DMD和Gravin（P
Lipoprotein lipase (LPL) is a prognostic marker in B-cell chronic lymphocytic leukemia (B-CLL) related to immunoglobulin V-H gene (IgV(H)) mutational status. We determined gene expression profiles using Affymetrix U133A GeneChips in two groups of B-CLLs selected for either high ('LPL+', n = 10) or low ('LPL-', n = 10) LPL mRNA expression. Selected genes were verified by real-time PCR in an extended patient cohort (n 42). A total of 111 genes discriminated LPL+ from LPL- B-CLLs. Of these, the top three genes associated with time to first treatment were Septin10, DMD and Gravin (P